title: Effects of polysulfated glycosaminoglycan and hyaluronan on prostaglandin E2 production by cultured equine synoviocytes.
abstract: OBJECTIVE
  To investigate effects of the anti-arthritic agents hyaluronan and polysulfated glycosaminoglycan (PSGAG) on inflammatory metabolism in cultured equine synoviocytes.
  
  
  METHODS
  Synoviocytes cultured from samples obtained from the metacarpophalangeal joints of 4 horses.
  
  
  METHODS
  Equine synoviocytes were grown in monolayer culture. Synoviocytes were stimulated with lipopolysaccharide (LPS) and simultaneously treated with various concentrations of hyaluronan or PSGAG for 48 hours. Three hyaluronan preparations were compared. Prostaglandin E2 (PGE2) concentrations in culture medium were measured, using radioimmunoassay.
  
  
  RESULTS
  The highest concentrations of hyaluronan and PSGAG tested inhibited PGE2 production.
  
  
  CONCLUSIONS
  Clinically achievable concentrations of hyaluronan and PSGAG inhibited PGE2 synthesis by cultured equine synoviocytes. This anti-inflammatory action may be a mechanism through which these agents exert anti-arthritic effects. The effect was obtained at concentrations that can be achieved by use of intra-articular, but not systemic, administration of hyaluronan or PSGAG.
authors.affiliation: Department of Veterinary Basic Sciences, Royal Veterinary College, North Mymms, Herts, UK.
authors.forename: S P
authors.initials: SP
authors.lastname: Frean
authors.forename: P
authors.initials: P
authors.lastname: Lees
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D002478:Cells, Cultured; D015232:Dinoprostone / Q000032:analysis / Q000096:biosynthesis*; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007213:Indomethacin / Q000494:pharmacology; D007270:Injections, Intra-Articular / Q000662:veterinary; D007596:Joints / Q000187:drug effects; D008070:Lipopolysaccharides / Q000494:pharmacology; D011863:Radioimmunoassay / Q000662:veterinary; D013583:Synovial Membrane / Q000166:cytology / Q000187:drug effects*
chemical_list: D000276:Adjuvants, Immunologic; D006025:Glycosaminoglycans; D008070:Lipopolysaccharides; C013786:A73025; D006820:Hyaluronic Acid; D015232:Dinoprostone; D007213:Indomethacin